TOP TEN perturbations for 1210_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1210_s_at
Selected probe(set): 227142_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1210_s_at (227142_at) across 6672 perturbations tested by GENEVESTIGATOR:

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.9678059
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.7820187
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.6989841
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

wound healing study 2 (ex vivo; AG1478) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-1.6945963
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; AG1478)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing AG1478 for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 10 micromolar AG1478 (dissolved in DMSO). The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. AG1478 is EGFR kinase inhibitor. ATC code:---
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

psoriasis study 20 (lesional) / psoriasis study 20 (non-lesional)

Relative Expression (log2-ratio):-1.6355829
Number of Samples:4 / 4
Experimental psoriasis study 20 (lesional)
Lesional skin punch biopsies derived from patients with chronic plaque psoriasis. 6 mm punch biopsies were obtained under local anesthesia preferentially near the central region of active plaques, except in cases where the center was poorly defined due to an irregular boundary. Regions near the edge of individual plaques were avoided to ensure that uninvolved skin was not included. Patients with one or more psoriasis plaques not limited to the scalp area were enrolled to the study. In case that only one plaque was present, a patient was admitted when that plaque occupied more than 1% of the body surface area. Patients were advised not to apply topical treatments for at least 1 week prior to biopsies and not to use systemic medications for at least 2 weeks prior to sample biopsies. Biopsies were snap-frozen in liquid nitrogen, stored at -80°C.
Control psoriasis study 20 (non-lesional)
Non-lesional skin punch biopsies derived from patients with chronic plaque psoriasis. 6 mm punch biopsies were obtained under local anesthesia from the buttocks and at least 10 cm away from the nearest active psoriasis plaque. Patients with one or more psoriasis plaques not limited to the scalp area were enrolled to the study. In case that only one plaque was present, a patient was admitted when that plaque occupied more than 1% of the body surface area. Patients were advised not to apply topical treatments for at least 1 week prior to biopsies and not to use systemic medications for at least 2 weeks prior to sample biopsies. Biopsies were snap-frozen in liquid nitrogen, stored at -80°C.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.6128654
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-1.5571012
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):-1.5528765
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

atopic dermatitis study 21 (lesional; epidermis) / normal epidermis tissue

Relative Expression (log2-ratio):-1.4468107
Number of Samples:5 / 10
Experimental atopic dermatitis study 21 (lesional; epidermis)
Lesional epidermal samples isolated from patient with moderate-to-severe chronic atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal epidermis tissue
Epidermal samples isolated from healthy subjects by laser capture microdissection.

influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.4371624
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

Organism: Homo sapiens
Gene: 1210_s_at
Selected probe(set): 219423_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1210_s_at (219423_x_at) across 6672 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-3.4536896
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

kidney transplantation study 11 (1 week) / normal blood sample

Relative Expression (log2-ratio):-3.288291
Number of Samples:11 / 5
Experimental kidney transplantation study 11 (1 week)
Whole blood samples derived from kidney transplant patients 1 week post-transplantation. Samples were collected 1 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal blood sample
Blood samples derived from healthy control subjects.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-3.13597
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.7867393
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):2.6331959
Number of Samples:11 / 6
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

kidney transplantation study 11 (2 week) / normal blood sample

Relative Expression (log2-ratio):-2.52312
Number of Samples:9 / 5
Experimental kidney transplantation study 11 (2 week)
Whole blood samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal blood sample
Blood samples derived from healthy control subjects.

DLBCL study 7 (GCB; naive-like) / DLBCL study 7 (GCB; centroblast-like)

Relative Expression (log2-ratio):2.4779205
Number of Samples:2 / 9
Experimental DLBCL study 7 (GCB; naive-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (germinal center B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to naive-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.
Control DLBCL study 7 (GCB; centroblast-like)
Primary tumor samples from patients with diffuse large B-cell lymphoma (germinal center B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to centroblast-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.

small cell lung cancer study 4 (2. gen. PDX) / small cell lung cancer study 4 (2. gen. CDX)

Relative Expression (log2-ratio):-2.423399
Number of Samples:4 / 12
Experimental small cell lung cancer study 4 (2. gen. PDX)
Xenografts (secondary) tumor tissue samples derived from a PDX-derived cell lines. A patient derived xenograft (PDX)-derived cell lines were grown under conventional tissue culture conditions for six months and then reimplanted to generate secondary xenografts (2. gen.).
Control small cell lung cancer study 4 (2. gen. CDX)
Xenografts (secondary) tumor tissue samples derived from a CDX-derived cell lines. A cell line derived xenograft (CDX)-derived cell lines were grown under conventional tissue culture conditions for six months and then reimplanted to generate secondary xenografts (2. gen.).

sangivamycin study 1 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):-2.4027119
Number of Samples:2 / 2
Experimental sangivamycin study 1
MCF7 cells treated with 2uM sangivamycin for 24 hours. ATC code:---
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

gefitinib study 2 / wild type A431 cell sample

Relative Expression (log2-ratio):-2.3732119
Number of Samples:3 / 3
Experimental gefitinib study 2
Gefitinib-resistant A431 (A431 GR) cells generated by growing parental cells in the presence of increasing concentrations of gefitinib up to 3 μM. Cells were selected and maintained in gefitinib (3μM). ATC code:
Control wild type A431 cell sample
A431 wild type cells.